LAG-3 ANTAGONIST THERAPY FOR LUNG CANCER

The disclosure provides a method of treating a human subject afflicted with lung cancer with a lymphocyte activation gene-3 (LAG-3) antagonist. In some aspects, the method comprises combination of the LAG-3 antagonist with an additional therapeutic agent (e.g., a programmed death-1 pathway inhibitor...

Full description

Saved in:
Bibliographic Details
Main Authors TOMS, LAURENCE DAVID, BASCIANO, PAUL ANDREW
Format Patent
LanguageEnglish
French
Published 28.04.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The disclosure provides a method of treating a human subject afflicted with lung cancer with a lymphocyte activation gene-3 (LAG-3) antagonist. In some aspects, the method comprises combination of the LAG-3 antagonist with an additional therapeutic agent (e.g., a programmed death-1 pathway inhibitor) and/or anti-cancer therapy (e.g., chemotherapy such as a platinum doublet chemotherapy). L'invention concerne un procédé de traitement d'un sujet humain atteint d'un cancer du poumon avec un antagoniste du gène d'activation lymphocytaire 3 (LAG-3). Dans certains aspects, le procédé comprend la combinaison de l'antagoniste de LAG-3 avec un agent thérapeutique supplémentaire (par exemple, un inhibiteur de la voie de mort programmée 1) et/ou une thérapie anticancéreuse (par exemple, une chimiothérapie telle qu'une chimiothérapie à doublet de platine).
Bibliography:Application Number: CA20213196496